Briacell Therapeutics Corp entered into an agreement to sell 762,500 common shares at $4.00 each, raising $3.05 million for working capital and business objectives. The offering closed on February 5, 2025, with a 7.5% fee paid to the placement agent and warrants issued for additional shares.